Cortendo AB

🇸🇪Sweden
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.cortendo.com

Bioavailability of Levoketoconazole and Ketoconazole Tablets

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-12-26
Last Posted Date
2020-01-31
Lead Sponsor
Cortendo AB
Target Recruit Count
34
Registration Number
NCT04212000
Locations
🇺🇸

Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States

Drug Interaction Study of Levoketoconazole and Metformin

First Posted Date
2019-03-19
Last Posted Date
2019-08-30
Lead Sponsor
Cortendo AB
Target Recruit Count
32
Registration Number
NCT03880825
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Levoketoconazole Food Effect Study in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-12-07
Last Posted Date
2019-02-04
Lead Sponsor
Cortendo AB
Target Recruit Count
22
Registration Number
NCT03768388
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Open-label Treatment in Cushing's Syndrome

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-08-08
Last Posted Date
2023-05-10
Lead Sponsor
Cortendo AB
Target Recruit Count
51
Registration Number
NCT03621280
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

🇫🇷

APHM Hôpital de la Conception, Marseille, France

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 27 locations

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

First Posted Date
2017-09-11
Last Posted Date
2022-11-08
Lead Sponsor
Cortendo AB
Target Recruit Count
84
Registration Number
NCT03277690
Locations
🇺🇸

University of Michigan, Comprehensive Endocrine Research, Internal Medicine - MEND, Ann Arbor, Michigan, United States

🇵🇱

Wojskowy Instytut Medyczny, Klinika Gastroenterologii, Endokrynologii I Chorob Wewnetrznych, Warsaw, Poland

🇬🇷

Evangelismos Athens General Hospital, Department of Endocrinology, Athens, Greece

and more 42 locations

Treatment for Endogenous Cushing's Syndrome

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-04-24
Last Posted Date
2021-04-19
Lead Sponsor
Cortendo AB
Target Recruit Count
94
Registration Number
NCT01838551
Locations
🇵🇱

Szpital Kliniczny im. Heliodora Swiecickiego, Poznań, Poland

🇺🇸

UCLA School of Medicine, Los Angeles, California, United States

🇺🇸

University of New Mexico HSC, Albuquerque, New Mexico, United States

and more 39 locations
© Copyright 2024. All Rights Reserved by MedPath